|
Authors, year | Type of study | | Comments |
|
Min et al., 2014 [11] | Retrospective cohort | 25 | Evaluated time to onset, frequency of resolution, and the effect of high-dose corticosteroids on clinical outcome |
|
Albarel et al., 2015 [12] | Retrospective (observational) | 15 | Characterized hypophysitis in terms of clinical signs, hormonal profile, and imaging at time of diagnosis and during long-term follow-up |
|
Chodakiewitz et al., 2014 [13] | Case series | 3 | Descriptive |
|
Nallapaneni et al., 2014 [14] | Case report | 1 | Describes a patient who developed uveitis and hypophysitis with anterior and posterior pituitary involvement without MRI findings |
|
Faje et al., 2014 [15] | Retrospective review | 17 | Descriptive |
|
Ryder et al., 2014 [16] | Retrospective | 19 | Descriptive |
|
Marlier et al., 2014 [17] | Case series | 4 | Descriptive |
|
Anderson and Bhatia, 2013 [18] | Case report | 1 | Descriptive |
|
Lammert et al., 2013 [7] | Case series | 7 | Discusses screening and management of hypophysitis in patients with metastatic cancer |
|
Corsello et al., 2013 [3] | Literature review | N/A | Review of existing literature on endocrine side effects induced by immune checkpoint inhibitors |
|
Van der Hiel et al., 2013 [9] | Case report | 1 | Descriptive |
|
Lotem et al., 2012 [19] | Descriptive | N/A | Description of CTLA-4 blockade as immunotherapy for malignant melanoma |
|
Andrews and Holden, 2012 [4] | Descriptive | N/A | Describes characteristics and management of immune related adverse effects related to ipilimumab |
|
Thomsen 2012 [20] | Case series | 2 | Descriptive |
|
Weber et al., 2012 [5] | Descriptive | N/A | Describes management of immune-related adverse events and kinetics of response with ipilimumab |
|
Juszczak et al., 2012 [21] | Case report and review | 1 | Descriptive |
|
Torino et al., 2012 [22] | Descriptive | N/A | Describes CTLA-4 induced hypophysitis as a new cause of a previously rare disease |
|
Bronstein et al., 2011 [23] | Case series | 2 | Describes radiologic manifestations of immune-related adverse events in patients with metastatic melanoma receiving anti-CTLA-4 antibody therapy |
|
Barnard et al., 2012 [10] | Case report | 1 | Hypophysitis presenting with hyponatremia |
|
Kähler and Hauschild, 2011 [1] | Descriptive | N/A | Reviews mechanisms of action with update on clinical trials and recommendations for managing side effects of anti-CTLA-4 antibody therapy |
|
Boasberg et al., 2010 [24] | Descriptive | N/A | Describes mechanism of action, immune response criteria, and side effect profile of anti-CTLA-4 agents |
|
Dillard et al., 2010 [6] | Case series | 2 | Patients with prostate cancer who develop hypopituitarism during treatment with ipilimumab |
|
Kaehler et al., 2009 [25] | Case report | 1 | Descriptive |
|
Carpenter et al., 2009 [8] | Case series | 3 | MRI findings in 3 patients with ipilimumab induced hypophysitis |
|
Yang et al., 2007 [26] | Case series | 2 | 2 patients with metastatic renal cell cancer and ipilimumab associated hypophysitis |
|